DUBLIN – Abalos Therapeutics GmbH raised €32.5 million (US$37.6 million) in a series A extension, taking the total raise to €43 million, enough to enable the company to generate clinical proof-of-concept data with its lead viral immunotherapy for cancer.

Jonathan Moore, who was employee No. 36 when he came to Vertex Inc. in 1990 and ended up spending the next 28 years at the company, realized he wasn’t done with his work in ATP-binding cassette (ABC) transporters and has now formed Rectify Pharmaceuticals Inc. The new company just closed on a $100 million series A financing to fund development of a pipeline of therapies to restore ABC transporter function for treating genetic diseases.

Biopharmas raising money in public or private financings, including: Alto, Anticancer, Bone, Cidara, Immunoprecise, Innocan, Maia, Osmotica, Petros, Sarepta and Topelia.

Med-tech firms raising money in public or private financings, including: Lark Health.

Biopharmas raising money in public or private financings, including: Axial, Bicycle, Relay, Rezolute, Sarepta, Xortx.

Biopharmas in Asia-Pacific raising money in public or private financings: Appili, Hangzhou Chance, Imophoron, Maxpro Capital Acquisition.

Med-tech firms raising money in public or private financings, including: Bisu, Octave Bioscience.

Biopharmas raising money in public or private financings, including: Bicycle, Cincor, Cingulate, Evofem, Mink, Rejuvenate, Relay, Sciwind.